Affiliation: RSBM
Email: pengchengshi@biotechrs.com; pcspc9@gmail.com
Abstract
Private label Oral Dissolving Films (ODFs) have emerged as a high-differentiation, fast-to-market product category across nutraceutical, consumer health, and nicotine-related sectors. Unlike in-house drug development, private label ODF projects rely on Original Equipment Manufacturer (OEM) partners to translate brand concepts into shelf-ready products under tight timelines and regulatory constraints. This paper presents a complete OEM roadmap for private label ODF development, covering concept definition, formulation strategy, equipment and process alignment, packaging and branding, quality assurance, and commercialization. By framing ODF OEM as a systems-engineering problem rather than a simple outsourcing task, this guide provides brand owners and OEM partners with a structured pathway to reduce risk, control cost, and achieve predictable market launch.
Introduction
Private label models allow brand owners to launch differentiated products without investing in manufacturing infrastructure. In recent years, ODFs have become an attractive private label format due to their portability, rapid action, precise dosing, and strong consumer novelty [1]. However, ODFs are also among the most process-sensitive oral dosage forms, and failures frequently occur when brand expectations are misaligned with formulation or manufacturing realities.
For OEM-based ODF projects, success depends on early integration of product positioning, formulation feasibility, process capability, packaging constraints, and regulatory pathways [2]. This paper addresses the key question faced by private label entrants: How can a brand systematically move from concept to shelf using an OEM ODF model while minimizing technical and commercial risk?
Methods
This work synthesizes peer-reviewed literature, pharmacopeial standards, and industrial OEM experience in ODF development. Common private label project workflows were analyzed, and failure points were mapped across development stages. Based on this analysis, a stepwise OEM roadmap was constructed, emphasizing decision gates, measurable outputs, and cross-functional alignment between brand owners and manufacturers [3].
Stage 1: Concept and Market Positioning
Product Definition
The OEM roadmap begins with precise product definition rather than ingredient selection. Key parameters include:
Target market (dietary supplement, OTC, nicotine, functional food)
Target consumer and use scenario
Value proposition (speed, convenience, taste, discretion)
Regulatory classification and claim boundaries
Clear positioning defines the technical envelope within which formulation and process design must operate [4].
SKU and Portfolio Planning
Private label success often depends on scalable SKU planning (e.g., flavor variants, strength tiers) rather than a single product. Early SKU mapping prevents costly redesign later in the project.
Stage 2: Formulation Strategy and Feasibility
Active Ingredient Assessment
OEM partners evaluate active ingredients for dose feasibility, solubility, taste impact, and stability in film matrices. Not all actives suitable for tablets or gummies are viable for ODFs [5].
Prototype Development
Laboratory-scale prototypes are developed to confirm:
Disintegration time
Mechanical integrity
Taste and mouthfeel
Preliminary stability
At this stage, the goal is feasibility, not optimization.
Stage 3: Process and Equipment Alignment
Scale-Up-Oriented Formulation Refinement
Formulations are adjusted to ensure compatibility with roll-to-roll coating, multi-zone drying, and high-speed cutting. Parameters such as viscosity window, coating weight, and drying tolerance are finalized [6].
Equipment Matching
OEM partners select or configure equipment based on:
Target capacity
Film thickness and strength
Packaging format
Misalignment between formulation and equipment is a leading cause of private label delays [7].
Stage 4: Packaging and Branding Integration
Packaging Selection
ODFs are highly sensitive to moisture and mechanical stress. Packaging formats (sachets, stick packs, blisters) are selected based on:
Shelf-life requirements
Consumer convenience
Regulatory labeling needs
Packaging is treated as a functional component of the dosage form, not a downstream aesthetic decision [8].
Artwork and Compliance
OEMs support artwork development to ensure consistency with regulatory requirements, including ingredient declaration, dosage instructions, and warnings.
Stage 5: Quality, Validation, and Regulatory Readiness
Quality Control Framework
Critical quality attributes (CQAs) for private label ODFs include:
Content uniformity
Disintegration time
Mechanical strength
Residual moisture
In-process controls and release testing protocols are established jointly by OEM and brand owner [9].
Regulatory Pathway
Depending on market and product type, documentation may include:
Product specifications
Stability data
Manufacturing flow and controls
Early regulatory alignment reduces the risk of post-launch disruptions [10].
Measures
Key performance indicators for OEM ODF projects include [11,12]:
Development cycle time
Pilot-to-commercial transfer success
Production yield and defect rate
Batch-to-batch consistency
On-time market launch
These measures reflect both technical and commercial performance.
Results
OEM projects that follow a structured roadmap demonstrate shorter development timelines, fewer reformulation cycles, and higher first-batch acceptance rates. In contrast, projects driven primarily by marketing concepts without early technical validation experience higher cost and delayed shelf entry [13].
Discussion
Private label ODF development is most successful when OEMs act as technical partners rather than contract producers. Early transparency regarding formulation limits, process windows, and packaging constraints enables realistic product positioning and sustainable brand growth [14].
From the brand perspective, the OEM roadmap transforms ODF development from an opaque outsourcing exercise into a managed innovation process with clear milestones and decision gates.
Conclusion
Private label ODFs offer compelling opportunities for brand differentiation, but only when developed through a disciplined OEM roadmap. By integrating concept definition, formulation feasibility, process alignment, packaging strategy, and quality systems, brands can reliably move from concept to shelf. This systems-driven approach reduces risk, controls cost, and enables scalable private label success in the rapidly growing oral film market.
References
Fu Y et al. Expert Opin Drug Deliv. 2004;1(4):673–690.
Preis M. J Pharm Pharmacol. 2013;65(2):157–170.
Cilurzo F et al. Eur J Pharm Biopharm. 2008;70(3):895–900.
Dixit RP, Puthli SP. J Control Release. 2009;139(2):94–107.
Bala R et al. Int J Pharm Investig. 2013;3(2):67–76.
Morales JO, McConville JT. Ther Deliv. 2011;2(5):637–646.
Hoffmann EM et al. Pharm Res. 2011;28(8):1914–1922.
Borges AF et al. Int J Pharm. 2015;494(1):332–339.
USP <701> Disintegration Test.
USP <905> Uniformity of Dosage Units.
Arya A et al. Int J PharmTech Res. 2010;2(1):576–583.
Preis M et al. Drug Dev Ind Pharm. 2014;40(2):152–160.
Keshari R, Keshari S. J Drug Deliv Ther. 2014;4(4):1–7.
Preis M. Drug Dev Ind Pharm. 2013;39(7):1049–1057.